Irinotecan

Generic Name
Irinotecan
Brand Names
Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)
Drug Type
Small Molecule
Chemical Formula
C33H38N4O6
CAS Number
97682-44-5
Unique Ingredient Identifier
7673326042
Background

Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).

Indication

For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.

Associated Conditions
Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma
Associated Therapies
-
Clinical Trials
Related News

Carmustine Wafers Plus Irinotecan in Treating Patients With Recurrent Supratentorial High Grade Gliomas

Phase 1
Completed
Conditions
Brain and Central Nervous System Tumors
First Posted Date
2003-09-25
Last Posted Date
2013-02-18
Lead Sponsor
Duke University
Registration Number
NCT00003463
Locations
🇺🇸

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

🇺🇸

Duke Comprehensive Cancer Center, Durham, North Carolina, United States

Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer

First Posted Date
2003-09-25
Last Posted Date
2020-04-29
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
1691
Registration Number
NCT00003594
Locations
🇺🇸

Hematology Oncology Associates of Illinois - Lake Shore Dr, Chicago, Illinois, United States

🇺🇸

Grady Memorial Hospital, Atlanta, Georgia, United States

🇺🇸

Emory University Hospital - Atlanta, Atlanta, Georgia, United States

and more 459 locations

Irinotecan in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma

Phase 2
Completed
Conditions
Lymphoma
First Posted Date
2003-09-24
Last Posted Date
2018-11-15
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
50
Registration Number
NCT00003245
Locations
🇺🇸

University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer

First Posted Date
2003-09-11
Last Posted Date
2018-12-04
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
225
Registration Number
NCT00068692
Locations
🇺🇸

Eastern Cooperative Oncology Group, Boston, Massachusetts, United States

Carboplatin Plus Irinotecan in Treating Patients With Glioblastoma Multiforme

Phase 2
Completed
Conditions
Brain and Central Nervous System Tumors
First Posted Date
2003-09-04
Last Posted Date
2011-03-28
Lead Sponsor
NYU Langone Health
Registration Number
NCT00010036
Locations
🇺🇸

NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States

Combination Chemotherapy in Treating Patients With Colorectal Cancer

First Posted Date
2003-09-03
Last Posted Date
2016-07-06
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
400
Registration Number
NCT00006103

S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy

First Posted Date
2003-08-07
Last Posted Date
2012-11-02
Lead Sponsor
SWOG Cancer Research Network
Target Recruit Count
45
Registration Number
NCT00066612

Irinotecan and Cisplatin in Treating Patients With Locally Advanced or Metastatic Penile Cancer

Phase 2
Completed
Conditions
Penile Cancer
First Posted Date
2003-08-07
Last Posted Date
2012-09-24
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Registration Number
NCT00066391
Locations
🇬🇧

Bristol Haematology and Oncology Centre, Bristol, England, United Kingdom

🇧🇪

U.Z. Gasthuisberg, Leuven, Belgium

🇭🇺

National Institute of Oncology, Budapest, Hungary

and more 5 locations

Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary

First Posted Date
2003-08-07
Last Posted Date
2017-04-04
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
31
Registration Number
NCT00066781
Locations
🇺🇸

Cancer Resource Center - Lincoln, Lincoln, Nebraska, United States

🇺🇸

Mercy Cancer Center at Mercy Medical Center - North Iowa, Mason City, Iowa, United States

🇺🇸

Mayo Clinic Cancer Center, Rochester, Minnesota, United States

and more 1 locations

Comparison of Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer

Phase 2
Completed
Conditions
Colorectal Cancer
First Posted Date
2003-08-07
Last Posted Date
2021-03-02
Lead Sponsor
UNICANCER
Registration Number
NCT00066274
Locations
🇫🇷

Centre Regional Francois Baclesse, Caen, France

🇫🇷

Centre Eugene Marquis, Rennes, France

🇫🇷

Centre Antoine Lacassagne, Nice, France

and more 14 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy